|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
ANRIL promotes AML development through HDAC1-mediated epigenetic suppression of ASPP2 via negatively regulating miR-34a, which might serve as a therapeutic target for AML treatment.
|
31830533 |
2020 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia.
|
31358016 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Together, these results demonstrate that HDAC1 is an important cofactor of CBFβ-SMMHC and a potential therapeutic target in inv (16) AML.
|
30814129 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Our study discovered that AML patients with lower expression of GFI-1 had higher level of HO-1, HDAC1, HDAC2 and HDAC3, which resulted in poor prognosis in AML.
|
29494986 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
We report that a low-dose chidamide, a novel orally active benzamide-type histone deacetylase (HDAC) inhibitor, which selectively targets HDACs 1, 2, 3, and 10, could enhance the cytotoxicity of DNA-damaging agents (daunorubicin, idarubicin, and cytarabine) in CD34<sup>+</sup>CD38<sup>-</sup> KG1α cells, CD34<sup>+</sup>CD38<sup>-</sup> Kasumi cells, and primary refractory or relapsed AML CD34<sup>+</sup> cells, reflected by the inhibition of cell proliferation, induction of apoptosis, and increase of cell cycle arrest in vitro.
|
28814980 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Together, these findings support the clinical evaluation of selective HDAC1/2 inhibitors in combination with azacitidine in AML patients.
|
28060870 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The gene repressors, HDAC1 and HDAC2, became recruited to the promoter of miR-182 to silence its expression in AML.
|
26858310 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Here, we found that HDAC1 expression was negatively correlated with that of Krüppel-like factor 4 (Klf4) and that AML patients with lower HDAC1 level had better prognosis.
|
25341045 |
2014 |
|
Leukemia, Myelocytic, Acute
|
0.090 |
Biomarker
|
disease |
BEFREE |
Taken together, these data support the notion that VPA might effectively target AML1/ETO-driven leukemogenesis through disruption of aberrant HDAC1 function and that VPA should be integrated in novel therapeutic approaches for AML1/ETO-positive AML.
|
17389244 |
2007 |